Retatrutide and IGF-1 LR3, as core products in the peptide field, hold an important position in global biological research, pharmaceutical R&D and other fields thanks to their unique molecular structures and excellent application performance.
The client in this cooperation is from the Netherlands and has been a loyal customer of our company. This marks their third purchase of related products from us, featuring highly efficient and smooth communication throughout the process and a very harmonious cooperative atmosphere. Based on their own research and application needs, the client clearly specified in their initial order the procurement of 6 vials of 10 mg Retatrutide, 1 vial of 1 mg IGF-1 LR3, and 4 vials of 10 mL bacteriostatic water (Bac water). Upon confirmation by both parties, the total price of this batch of products was USD 1,440. During order confirmation, payment and inventory verification, the client responded promptly, while our company synchronized inventory status and order progress in a timely manner to ensure efficient progress of the cooperation process.
After order confirmation and payment completion, the client placed a supplementary order for an additional 1 box of 60 mg Retatrutide according to their needs. Our company quickly checked inventory and confirmed supply capacity, successfully completing the follow-up of the additional order. The highly efficient and professional service throughout the process has been highly recognized by the client.
I. Detailed Analysis of Core Product Applications
(1) Core Applications of Retatrutide
As a novel triple hormone receptor agonist, Retatrutide is mainly used in clinical research and scientific exploration of metabolism-related diseases. Through the synergistic activation of three hormone receptors, it demonstrates application potential far exceeding that of single-receptor agonists.
In obesity research, Retatrutide helps improve metabolic disorders by regulating the appetite center, reducing food intake and increasing energy expenditure. It has shown significant weight-loss effects in Phase II clinical trials, providing an important research direction for new therapeutic regimens for obesity.
In Type 2 diabetes research, the product effectively regulates blood glucose levels and improves insulin resistance by promoting insulin secretion and inhibiting glucagon secretion. Eli Lilly and Company has recently released topline results from Phase III clinical trials for Type 2 diabetes, laying a foundation for its subsequent clinical application.
In addition, Retatrutide has shown promising prospects in research on other metabolism-related diseases, including pain associated with knee osteoarthritis, moderate to severe obstructive sleep apnea, chronic low back pain, and metabolic dysfunction-associated steatotic liver disease. All are currently in clinical research stages and are expected to offer novel therapeutic strategies for these conditions.
(2) Core Applications of IGF-1 LR3
As a genetically engineered optimized peptide molecule, IGF-1 LR3 is mainly applied in tissue regeneration, cell biology research, preclinical drug development and other fields. Its potent anabolic and anti-catabolic effects make it an important tool in scientific research and industrial applications.
In basic and translational medical research, IGF-1 LR3 widely supports the growth of various cell lines - including myoblasts, chondrocytes and neuronal precursor cells - under low-serum or serum-free conditions. It is used to study mechanisms of cell proliferation, survival and differentiation, and can precisely activate downstream signaling pathways such as PI3K/Akt and MAPK/ERK, providing strong support for research on metabolism, aging and related fields.
In tissue engineering and regenerative medicine, IGF-1 LR3 is a key component of serum-free cell culture systems. It is often used in combination with growth factors such as FGF and TGF-β to optimize the efficiency of stem cell expansion and directed differentiation. It also supports the construction of 3D organoids, providing essential survival and proliferation signals for culturing hepatocytes, intestinal epithelial cells and other organoid models.
In bioprocess manufacturing, the product serves as a medium supplement for large-scale culture of mammalian cells such as CHO cells, improving cell density and viability and thus increasing recombinant protein yield. It is also used for the in vitro expansion of therapeutic cells including CAR-T cells and stem cells, ensuring the quality and activity of cell products.
Furthermore, in muscle and skeletal biology research, IGF-1 LR3 promotes skeletal muscle regeneration and increases bone mineral density, serving as a valuable experimental tool for studies on sarcopenia, osteoporosis and related diseases. In neuroscience, it supports neuronal survival and neurite outgrowth, aiding research on neurodegenerative diseases such as Alzheimer's disease.
II. Outlook on Product Development Prospects
As a novel triple hormone receptor agonist, Retatrutide is expected to achieve major breakthroughs in the treatment of metabolic diseases with its multi-target synergistic advantages, boasting enormous market potential. According to current clinical progress, multiple Phase II trials have been successfully completed, and Phase III trials are underway in an orderly manner. Topline results for obesity and Type 2 diabetes have been gradually released, demonstrating excellent efficacy and favorable safety profiles. Upon successful approval by regulatory authorities worldwide, it will become a key drug in metabolic disease treatment, with rapid expansion of its market scale.
As an important tool reagent for scientific research and industrial applications, IGF-1 LR3 will see continuously growing market demand and broad development prospects alongside the rapid advancement of biological research, tissue engineering, cell therapy and related fields. Globally, investment in life sciences, cell biology, molecular biology and regenerative medicine keeps increasing. As an indispensable experimental tool, demand for IGF-1 LR3 will rise steadily with expanded research activities, especially in high-potential areas including stem cell research, oncology and neuroscience.
III. Cooperation Summary and Future Prospects
This third cooperation with the Dutch client represents high recognition of the quality of our products such as Retatrutide and IGF-1 LR3, as well as full affirmation of our service capabilities. As a long-term partner, the client's three orders have all centered on our core products, fully reflecting the important role of Retatrutide and IGF-1 LR3 in their research work. Smooth communication, efficient order execution and reliable product delivery have further deepened mutual trust, laying a solid foundation for sustained and stable cooperation in the future.
Amid growing market demand for Retatrutide and IGF-1 LR3 and the rapid development of the global peptide industry, we will seize industrial opportunities, strengthen technological innovation and product R&D, expand our overseas market layout, and deepen cooperation with global customers - especially strengthening partnerships with key regional clients in Europe. We aim to support customers in achieving more breakthroughs in research and application while realizing our own sustainable development.
We firmly believe that, with high-quality products, professional services and a sincere cooperative attitude, we will establish long-term and stable partnerships with more overseas clients, and jointly promote technological progress and industrial development in the peptide field.
